Publications by authors named "Carpo M"

Background And Purpose: This study aimed to assess the diagnostic criteria, ancillary investigations and treatment response using real-life data in multifocal motor neuropathy (MMN) patients.

Methods: Clinical and laboratory data were collected from 110 patients enrolled in the Italian MMN database through a structured questionnaire. Twenty-six patients were excluded due to the unavailability of nerve conduction studies or the presence of clinical signs and symptoms and electrodiagnostic abnormalities inconsistent with the MMN diagnosis.

View Article and Find Full Text PDF
Article Synopsis
  • The 2021 EAN/PNS guidelines provide detailed clinical criteria to diagnose various variants of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), despite the lack of research on their treatment impact.
  • In a study involving 369 patients from the Italian CIDP database, 66% were diagnosed with different CIDP variants using these new criteria, revealing a distribution of typical and atypical forms.
  • The findings indicate that patients with multifocal, distal, and sensory CIDP often experience milder symptoms and may respond differently to steroid treatments compared to those with other variants, underscoring the need for specific guidelines in managing CIDP.
View Article and Find Full Text PDF

Background: To assess the ability of the 2021 European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) clinical criteria for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) to include within their classification the whole spectrum of clinical heterogeneity of the disease and to define the clinical characteristics of the unclassifiable clinical forms.

Methods: The 2021 EAN/PNS clinical criteria for CIDP were applied to 329 patients fulfilling the electrodiagnostic (and in some cases also the supportive) criteria for the diagnosis of CIDP. Clinical characteristics were reviewed for each patient not strictly fulfilling the clinical criteria ('unclassifiable').

View Article and Find Full Text PDF
Article Synopsis
  • - The study aimed to assess the risks and safety of SARS-CoV-2 vaccination for patients with chronic inflammatory neuropathies, particularly looking at relapse rates before and after vaccination.
  • - Involved 336 patients, with 91% vaccinated; 5% experienced mild relapses post-vaccination, while no relapses occurred in unvaccinated patients, indicating a relative risk increase for those who did receive the vaccine.
  • - Overall, the vaccination didn’t strongly correlate with an increased relapse risk, although CIDP patients showed a slightly higher risk compared to the three months before getting vaccinated, with mild side effects being the main safety concerns.
View Article and Find Full Text PDF

Many in the design community have long claimed that digital mass-customization is cheaper, faster, smarter and more environmentally sustainable than the mechanical mass-production of standardized industrial products; and that the electronic transmission of information is cheaper, faster, smarter, and more environmentally sustainable than the mechanical transportation of people and goods. The global pandemic has tragically proven that a computational alternative to the modern, mechanical way of making, working, and living, now exists, and it is viable. When we had to shut down corporate offices, global megafactories, suburban shopping malls, and intercontinental airports, we did.

View Article and Find Full Text PDF
Article Synopsis
  • * GBS cases from March 2020 to March 2021 showed a 59% increase compared to the previous year, with approximately 50% of GBS patients testing positive for COVID-19.
  • * The study concluded that GBS incidence rose during the pandemic, indicating a significant association between GBS and COVID-19, as non-COVID-19 GBS cases decreased during the same period.
View Article and Find Full Text PDF
Article Synopsis
  • The study examined 276 Italian patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) for the presence of anti-nerve autoantibodies and correlated findings with clinical data.
  • Anti-neurofascin155 (NF155) and anti-contactin1 (CNTN1) antibodies were found in a small percentage of patients, with specific clinical symptoms linked to each type of antibody.
  • The presence of these antibodies suggests that CIDP may have various underlying mechanisms, leading to different clinical manifestations in patients.
View Article and Find Full Text PDF

The World Health Organization and Centers for Disease Control and Prevention consider the global increase in multidrug-resistant organisms (MDROs) to be one of the greatest modern threats to public health. Limited treatment options exist for microorganisms such as carbapenem-resistant Enterobacterales and Candida auris; as a result, infected patients may experience poor outcomes. Perioperative nurses should use infection prevention measures (eg, contact precautions) to prevent the spread of emerging MDROs when transporting patients to and from procedures, caring for patients during procedures, and completing between-procedure cleaning.

View Article and Find Full Text PDF

Compression of the median nerve at the carpal tunnel can give demyelinating features and result in distal motor latency (DML) prolongation fulfilling the EFNS/PNS demyelinating criteria for chronic inflammatory demyelinating polyneuropathy (CIDP). Accordingly, being carpal tunnel syndrome (CTS) common in the general population, the EFNS/PNS guidelines recommend excluding the DML of the median nerve when DML prolongation may be consistent with median neuropathy at the wrist from CTS. The main aims of this study were to verify whether the inclusion of DML of the median nerve (when consistent with CTS) could improve electrophysiological diagnostic accuracy for CIDP and if the median nerve at the carpal tunnel was more prone to demyelination.

View Article and Find Full Text PDF

Introduction: Electrophysiological diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) may be challenging. Thus, with the aim ofproviding some practical advice in electrophysiological approach to a patient with suspected CIDP, we analyzed electrophysiological data from 499 patients enrolled inthe Italian CIDP Database.

Methods: We calculated the rate of each demyelinating feature, the rate of demyelinating features per nerve, the diagnostic rate for upper andlower limb nerves, and, using a ROC curve analysis, the diagnostic accuracy of each couple of nerves and each demyelinating feature, for every CIDP subtype.

View Article and Find Full Text PDF

Objective: Single cases and small series of Guillain-Barré syndrome (GBS) have been reported during the SARS-CoV-2 outbreak worldwide. We evaluated incidence and clinical features of GBS in a cohort of patients from two regions of northern Italy with the highest number of patients with COVID-19.

Methods: GBS cases diagnosed in 12 referral hospitals from Lombardy and Veneto in March and April 2020 were retrospectively collected.

View Article and Find Full Text PDF

Objective: To validate sphingomyelin (SM) dosage in the cerebrospinal fluid (CSF) of patients affected by chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and Guillain-Barré syndrome (GBS) as a reliably assessable biomarker.

Methods: We prospectively enrolled 184 patients from six Italian referral centres, in whom CSF SM levels were quantified by a fluorescence-based assay optimised and patented in our laboratory.

Results: We confirmed increased levels of SM in the CSF of patients affected by typical CIDP (n=35), atypical CIDP (n=18) and acute inflammatory demyelinating polyradiculoneuropathy, AIDP (n=12) compared with patients affected by non-demyelinating neurological diseases, used as controls (n=85) (p<0.

View Article and Find Full Text PDF

Background And Purpose: The aim was to identify the clinical and diagnostic investigations that may help to support a diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in patients not fulfilling the European Federation of Neurological Societies and Peripheral Nerve Society (EFNS/PNS) electrodiagnostic criteria.

Methods: The data from patients with a clinical diagnosis of CIDP included in a national database were retrospectively reviewed.

Results: In all, 535 patients with a diagnosis of CIDP were included.

View Article and Find Full Text PDF
Article Synopsis
  • A study was conducted to examine the prevalence of comorbidities in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and how these comorbidities impact treatment and outcomes.
  • Of the 393 CIDP patients surveyed, 75% reported having at least one comorbidity, which affected treatment choices for nearly 49% of them, particularly reducing the use of corticosteroids.
  • Notably, diabetes, monoclonal gammopathy of undetermined significance (MGUS), and other immune disorders were found to be more common in CIDP patients compared to the general population, with diabetes negatively influencing disability and treatment response.
View Article and Find Full Text PDF

A few observational studies and randomized trials suggest that exercise and rehabilitation may improve activity limitation and quality of life (QoL) in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), but the impact of other modifiable factors on the severity of the disease is not well understood. Using a structured questionnaire, we collected data on lifestyle and dietary habits of the patients included in the Italian CIDP database to investigate the possible influence of modifiable lifestyle factors on disability and QoL. Questionnaire data were available for 323 patients.

View Article and Find Full Text PDF

Background and aims to report the clinical features and the relevance of diagnostic investigations in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). We retrospectively reviewed data from patients with a clinical diagnosis of CIDP included in a national database. Among the 500 included patients with a clinical diagnosis of CIDP, 437 patients (87%) fulfilled the EFNS/PNS criteria for CIDP (definite in 407, probable in 26, possible in four).

View Article and Find Full Text PDF
Article Synopsis
  • - The study aimed to investigate the presence and types of anti-nodal/paranodal antibodies in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and to compare clinical features between those with and without these antibodies.
  • - Among 342 CIDP patients, 19 (5.5%) tested positive for specific antibodies, predominantly IgG4, which were linked to severe symptoms and poor treatment response; these antibodies were absent in healthy controls or other neuropathy patients.
  • - The findings suggest that IgG4 antibodies may be pathogenic, as they were associated with significant morphological changes in skin biopsies, and early immunosuppressive treatment was effective for patients resistant to standard IVIG therapy.
View Article and Find Full Text PDF

Objectives: Anti-myelin-associated glycoprotein (MAG) antibody is associated with clinically heterogeneous polyneuropathies. Our purpose was to compare neuropathy phenotypes identified by different anti-MAG tests' results.

Methods: Cohort study: Sera from 40 neuropathy anti-MAG EIA positive patients were tested for anti-MAG by Western blot (WB), for anti-peripheral nerve myelin (PNM) on monkey nerve by immunofluorescence assay (IFA), and for anti-HNK1 on rat CNS slices by IFA.

View Article and Find Full Text PDF

Background And Purpose: The role of lifestyle and dietary habits and antecedent events has not been clearly identified in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).

Methods: Information was collected about modifiable environmental factors and antecedent infections and vaccinations in patients with CIDP included in an Italian CIDP Database. Only patients who reported not having changed their diet or the lifestyle habits investigated in the study after the appearance of CIDP were included.

View Article and Find Full Text PDF

Objectives: A few variants of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) have been described, but their frequency and evolution to typical CIDP remain unclear. To determine the frequency and characteristics of the CIDP variants, their possible evolution to typical CIDP, and treatment response.

Methods: We applied a set of diagnostic criteria to 460 patients included in a database of Italian patients with CIDP.

View Article and Find Full Text PDF

We tested autoantibodies to neurofascin-186 (NF186) and gliomedin in sera from patients with multifocal motor neuropathy (MMN, n=53) and chronic inflammatory demyelinating polyneuropathy (CIDP, n=95) by ELISA. IgG antibodies to NF186 or gliomedin were found in 62% of MMN and 1% of CIDP sera, and IgM antibodies to the same antigens in 12% of MMN and 1% of CIDP sera. These autoantibodies activated complement.

View Article and Find Full Text PDF

Pain is a subjective condition that cannot be objectively measured; for this reason, self patient-perspective is crucial. Recently, several screening tools to discriminate between nociceptive and neuropathic pain have been developed. We aimed at assessing the consistence and discrepancy of two widely used screening tools, The Douleur Neuropathique 4 (DN4) and the 6-item questionnaire (ID-Pain), by comparing their ability in discriminating neuropathic from nociceptive pain.

View Article and Find Full Text PDF

Background: A 57-year-old woman presented with metastatic renal cell carcinoma (RCC). She was enrolled in a clinical study, in which she received two cycles of neoadjuvant sunitinib therapy followed by cytoreductive nephrectomy. Her primary tumor and rib metastasis showed a good response to neoadjuvant therapy; however, after surgery, the patient developed neurologic symptoms, including flaccid paraparesis with paresthesia and hypoesthesia.

View Article and Find Full Text PDF

We evaluated serum glial fibrillary acidic protein (GFAP) levels by enzyme-linked immunosorbent assay (ELISA) in controls (n = 30) and in patients with chronic sensory-motor axonal neuropathy (CSMAN) (n = 30), chronic inflammatory demyelinating polyneuropathy (CIDP) (n = 30), multifocal motor neuropathy (MMN) (n = 30), and primary muscular spinal atrophy (PMSA) (n = 15). GFAP levels, expressed as optical density, were increased in CSMAN (median = 1.05) compared to controls (median = 0.

View Article and Find Full Text PDF